Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Key Takeaway
Learn about the FDA's Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) designed to curb opioid misuse by ensuring safe prescribing, dispensing, and patient monitoring practices. This initiative targets healthcare professionals and aims to improve patient safety and opioid education.
What This Means for Cannabis Businesses
Federal policy changes ripple across the entire cannabis industry. Whether it's rescheduling progress, banking legislation, or court rulings, these developments shape the operating environment for businesses in every legal state. Operators should monitor these developments closely and consult with their legal counsel to understand the implications for their specific markets and operations.
Related Guides
Find Help
Related News
Congressman Presses DOJ and DEA on Cannabis Rescheduling Timeline
New Congressional Research Report on Cannabis Rescheduling Published
Congressional Research Service Releases Comprehensive Cannabis Rescheduling Report
Virginia Legislature Sends Cannabis Sales Legalization Bill to Governor
This analysis is based on reporting by FDA. Read the original article. CannaBizGuide provides original commentary and analysis - this is not legal or tax advice.